Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Instagram Outage Disrupts Thousands of U.S. Users 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
 announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Feb. 14, 2017 -- The Shareholders Foundation, Inc. announces that a lawsuit is pending in Colorado on behalf of certain purchasers of shares of Clovis Oncology Inc (NASDAQ:CLVS) over alleged Securities Laws Violations by Clovis Oncology.
Investors who purchased shares of Clovis Oncology Inc (NASDAQ:CLVS) before May 2014 and continue to hold any NASDAQ:CLVS shares have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
On November 19, 2015, a lawsuit was filed against Clovis Oncology Inc over alleged securities laws violations. The plaintiff claimed that the defendants allegedly made false and misleading statements and/or failed to disclose that the NDA that Clovis submitted to the FDA for rociletinib contained immature data sets based on both unconfirmed response rates and confirmed response rates, that Clovis Oncology’s Breakthrough Therapy designation submission contained immature data sets based primarily on unconfirmed responses, that Clovis Oncology presented interim data publicly and at medical meetings that included a data set based primarily on unconfirmed responses, that as the efficacy data matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected, and that as a result of the foregoing, Clovis Oncology’s NDA was likely to be delayed and/or rejected by the FDA. On July 27, 2016, the defendants filed their motions to dismiss the case. On February 9, 2017, the judge presiding over the case refused to dismiss the lawsuit.
Those who purchased Clovis Oncology Inc (NASDAQ:CLVS) shares should contact the Shareholders Foundation, Inc. by e-mail at [email protected] or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
